Research News and Research

RSS

Damp, moldy homes lead to depression

A groundbreaking public health study has found a connection between damp, moldy homes and depression.

30 Aug 2007

Biologic treatment for rheumatoid arthritis and the risk of cancer

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated.

30 Aug 2007

New understanding of endoplasmic reticulum

In obese individuals, fat cells are bloated and inflamed because they receive too many nutrients, including lipids.

29 Aug 2007

Why we remember bad events

Do you remember exactly where you were when you learned of the Sept. 11 terrorist attacks?

29 Aug 2007

Fingolimod shows promise in 2 lethal leukemias

A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia.

29 Aug 2007

Pycnogenol reduces perimenopausal symptoms

A study to be published in an upcoming edition of the Scandinavian Journal of Obstetrics and Gynaecology reveals that Pycnogenol (pic-noj-en-all), pine bark extract from the French maritime pine tree, reduces "climacteric symptoms" such as hot flashes, depression, panic attacks, cholesterol and other common symptoms associated with women entering menopause transition.

29 Aug 2007

Skin-healing pseudoceramides

Researchers report in the September 2007 issue of the Journal of Lipid Research that they have made synthetic lipids called pseudoceramides that are involved in skin cell growth and could be used in treating skin diseases in which skin cells grow abnormally.

29 Aug 2007

Lipid offers new ways of treating inflammatory kidney diseases

Scientists report in the September 2007 issue of the Journal of Lipid Research that a lipid known to protect the heart from inflammation and to cause skin allergic reactions also reduces inflammation of the kidneys.

29 Aug 2007

'Mighty mice' made mightier

The Johns Hopkins scientist who first showed that the absence of the protein myostatin leads to oversized muscles in mice and men has now found a second protein, follistatin, whose overproduction in mice lacking myostatin doubles the muscle-building effect.

29 Aug 2007

For some being uninsured is a matter of choice

"While it is true that the number of uninsured has grown, it is equally true that the number of people with insurance has continued to grow steadily," said NCPA Senior Fellow Devon Herrick.

29 Aug 2007

HPV vaccines may lower risk of oral cancer

The Centers for Disease Control report that nearly 25 million women are infected with some form of the Human Papilloma Virus (HPV).

29 Aug 2007

High-risk behaviors among injection drug users in Afghanistan

In a report that is among the first to describe the prevalence of HIV and Hepatitis B and C viruses in Afghanistan, a researcher from the University of California, San Diego (UCSD) School of Medicine voiced concerns that increasing injection drug use and accompanying high-risk behavior could lead to an HIV epidemic in Afghanistan.

29 Aug 2007

How does Listeria monocytogenes survive with nothing to live on?

Try going for a couple of weeks without food and see what shape you're in, or if you're around at all by then. Let some dangerous bacteria do the same thing and there's a chance they may do more than survive; they can grow stronger and remain as virulent as ever.

29 Aug 2007

FDA approves cobas TaqScreen WNV test for West Nile virus

The U.S. Food and Drug Administration has announced approval of a second test for the detection of West Nile virus (WNV) in blood and organs.

29 Aug 2007

UK follows Australia's lead on graphic visual warnings on tobacco packaging

Graphic images illustrating the devastating effects that tobacco can have on health will be printed on all tobacco packets from next year Health Secretary Alan Johnson announced today.

29 Aug 2007

St. Jude discovers factors that accelerate resistance to Gleevec targeted therapy in lymphoblastic leukemia

Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the drug imatinib (Gleevec), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).

29 Aug 2007